Sign In
Buy RETA
$172.36
+0 (+0%)
At Close: Dec 22, 2023
Reata Stock Plummets As Official's Exit Shakes Up FDA's Neuroscience Unit
12:47pm, Monday, 27'th Feb 2023
The FDA will decide whether to approve a neurological disease drug from Reata Pharmaceuticals this week, but RETA stock plummeted Monday. The post Reata Stock Plummets As Official's Exit Shakes Up FDA
Market Insanity: Buying Stocks at 100 Times Revenue
10:44am, Monday, 20'th Feb 2023
There are no sure things in the stock market. But here's an almost sure thing: Investing in stocks that sell for 100 times revenue will lead you to grief.
Reata Pharmaceuticals, Inc. (RETA) Soars 6.3%: Is Further Upside Left in the Stock?
06:02am, Friday, 03'rd Feb 2023
Reata Pharmaceuticals, Inc. (RETA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into furthe
Reata Pharmaceuticals: Binary Catalyst Unlocking
09:39am, Sunday, 22'nd Jan 2023
Bardoxolone's Complete Response Letter caused the stock to lose much of its share price last year. The other lead medicine (omaveloxolone) is going to the FDA for Friedrich's Ataxia approval this Febr
Reata Pharmaceuticals: Buy While Preparing For First Commercial Launch
08:30pm, Tuesday, 03'rd Jan 2023
Reata Pharmaceuticals has an FDA decision (PDUFA) date of February 28 for omaveloxolone. Bardoxolone is in three Phase 3 trials for different types of polycystic kidney disease.
Reata Pharmaceuticals, Inc. (RETA) Down 1.3% Since Last Earnings Report: Can It Rebound?
04:30pm, Thursday, 08'th Dec 2022 Zacks Investment Research
Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reata Pharmaceuticals To Jump 220%? Plus JP Morgan Predicts $51 For Las Vegas Sands
02:14pm, Monday, 28'th Nov 2022 Benzinga
Goldman Sachs boosted the price target on Reata Pharmaceuticals, Inc. (NASDAQ: RETA) from $86 to $115. Goldman Sachs analyst Madhu Kumar maintained the stock with a Buy rating. Reata Pharmaceuticals
Analyst Ratings for Reata Pharmaceuticals
02:03pm, Monday, 28'th Nov 2022 Benzinga
Over the past 3 months, 5 analysts have published their opinion on Reata Pharmaceuticals (NASDAQ:RETA) stock. These analysts are typically employed by large Wall Street banks and tasked with understan
Reata (RETA) Q3 Earnings Beat, Stock Up on Pipeline Updates
03:55pm, Wednesday, 09'th Nov 2022 Zacks Investment Research
Reata (RETA) reports a narrower-than-expected loss in the third quarter. Stock rises after RETA states that the FDA did not request additional data on the NDA for omaveloxolone in Friedreich's ataxia.
Planet Fitness To Surge Over 25%? Plus Morgan Stanley Cuts PT On This Stock By 50%
01:44pm, Wednesday, 09'th Nov 2022 Benzinga
Raymond James raised the price target on Planet Fitness, Inc. (NYSE: PLNT) from $70 to $84. Raymond James analyst Joseph Altobello maintained a Strong Buy rating on the stock. Planet Fitness shares
Reata (RETA) Q3 Earnings Beat, Stock Up on Pipeline Updates
12:02pm, Wednesday, 09'th Nov 2022
Reata (RETA) reports a narrower-than-expected loss in the third quarter. Stock rises after RETA states that the FDA did not request additional data on the NDA for omaveloxolone in Friedreich's ataxia.
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
10:08am, Wednesday, 09'th Nov 2022 Benzinga
Gainers
Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday.
TaskUs, Inc. (NAS
DuPont, Expeditors International, Planet Fitness And Other Big Gainers From Tuesday
07:53am, Wednesday, 09'th Nov 2022 Benzinga
U.S. stocks closed higher on Tuesday, with the Dow Jones surging more than 300 points. Here is the list of some big stocks recording gains in the previous session.
TaskUs, Inc. (NASDAQ: TASK) shares
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session
05:51pm, Tuesday, 08'th Nov 2022 Benzinga
Gainers
IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 39.4% to $1.4529 after the company announced a payment assignment from the Centers for Medicare & Medicaid Services for the ProSense breast ca
Reata Pharmaceuticals, Inc. (RETA) Q3 2022 Earnings Call Transcript
04:50pm, Tuesday, 08'th Nov 2022
Reata Pharmaceuticals, Inc. (NASDAQ:RETA ) Q3 2022 Results Conference Call November 8, 2022 8:30 AM ET Company Participants Warren Huff - Chief Executive Officer Manmeet Soni - President Colin Meyer -
